Cargando…

Loss of MHC-I antigen presentation correlated with immune checkpoint blockade tolerance in MAPK inhibitor-resistant melanoma

Immune checkpoint blockade and MAPK-targeted combined therapy is a promising regimen for advanced melanoma patients. However, the clinical benefit from this combo regimen remains limited, especially in patients who acquired resistance to MAPK-targeted therapy. Here, we systematically characterized t...

Descripción completa

Detalles Bibliográficos
Autores principales:	Yu, Jing, Wu, Xi, Song, Jinen, Zhao, Yujie, Li, Huifang, Luo, Min, Liu, Xiaowei
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Frontiers Media S.A. 2022
Materias:	Pharmacology
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9459091/ https://www.ncbi.nlm.nih.gov/pubmed/36091815 http://dx.doi.org/10.3389/fphar.2022.928226

Ejemplares similares

Understanding the Impact of ErbB Activating Events and Signal Transduction on Antigen Processing and Presentation: MHC Expression as a Model
por: Kersh, Anna E., et al.
Publicado: (2016)

Resistance to checkpoint blockade therapy through inactivation of antigen presentation
por: Sade-Feldman, Moshe, et al.
Publicado: (2017)

Combination of phototherapy with immune checkpoint blockade: Theory and practice in cancer
por: Zhao, Yujie, et al.
Publicado: (2022)

Nanoformulation improves antitumor efficacy of MAOI immune checkpoint blockade therapy without causing aggression-related side effects
por: Brown, James, et al.
Publicado: (2022)

Editorial: Improvement of melanoma immune checkpoint blockade therapy with potential combinatorial regiments
por: Wang, Xueyan, et al.
Publicado: (2022)

The Role of Immune Checkpoint Blockade in Uveal Melanoma
por: Wessely, Anja, et al.
Publicado: (2020)

Tamarixinin A Alleviates Joint Destruction of Rheumatoid Arthritis by Blockade of MAPK and NF-κB Activation
por: Zhuang, Yuanyuan, et al.
Publicado: (2017)

Trends in the Research Into Immune Checkpoint Blockade by Anti-PD1/PDL1 Antibodies in Cancer Immunotherapy: A Bibliometric Study
por: Sun, Yiting, et al.
Publicado: (2021)

Focused ultrasound-mediated small-molecule delivery to potentiate immune checkpoint blockade in solid tumors
por: Wu, Qiuyu, et al.
Publicado: (2023)

The Differences in the Safety and Tolerability of Immune Checkpoint Inhibitors as Treatment for Non–Small Cell Lung Cancer and Melanoma: Network Meta-Analysis and Systematic Review
por: Chai, Qing-Qing, et al.
Publicado: (2019)

MEK inhibition enhances presentation of targetable MHC-I tumor antigens in mutant melanomas
por: Stopfer, Lauren E., et al.
Publicado: (2022)

Inflammatory B cells correlate with failure to checkpoint blockade in melanoma patients
por: de Jonge, Kaat, et al.
Publicado: (2021)

Cancer Immune Evasion Through Loss of MHC Class I Antigen Presentation
por: Dhatchinamoorthy, Karthik, et al.
Publicado: (2021)

Gene signature of antigen processing and presentation machinery predicts response to checkpoint blockade in non-small cell lung cancer (NSCLC) and melanoma
por: Thompson, Jeffrey C, et al.
Publicado: (2020)

Antigen Processing by Macroautophagy for MHC Presentation
por: Münz, Christian
Publicado: (2011)

Antigen processing for MHC presentation by autophagy
por: Münz, Christian
Publicado: (2010)

Antigen Presentation by MHC-Dressed Cells
por: Nakayama, Masafumi
Publicado: (2015)

Current Insights into Combination Therapies with MAPK Inhibitors and Immune Checkpoint Blockade
por: Shin, Min Hwa, et al.
Publicado: (2020)

Predictors of responses to immune checkpoint blockade in advanced melanoma
por: Jacquelot, N., et al.
Publicado: (2017)

Predictive factors of neoadjuvant immune checkpoint blockade in melanoma
por: Sarver, Melissa, et al.
Publicado: (2021)

β-Glucan Combined With PD-1/PD-L1 Checkpoint Blockade for Immunotherapy in Patients With Advanced Cancer
por: Wang, Mengjie, et al.
Publicado: (2022)

In-situ formed thermosensitive hydrogel amplifies statin-mediated immune checkpoint blockade for coordinated tumor chemo-immunotherapy
por: Liu, Zefan, et al.
Publicado: (2023)

Loss of antigen-presenting molecules (MHC class I and TAP-1) in lung cancer.
por: Korkolopoulou, P., et al.
Publicado: (1996)

The Macroautophagy Machinery in MHC Restricted Antigen Presentation
por: Münz, Christian
Publicado: (2021)

DHODH inhibition enhances the efficacy of immune checkpoint blockade by increasing cancer cell antigen presentation
por: Mullen, Nicholas J., et al.
Publicado: (2023)

Combinatorial Strategies With PD-1/PD-L1 Immune Checkpoint Blockade for Breast Cancer Therapy: Mechanisms and Clinical Outcomes
por: Zheng, Dan, et al.
Publicado: (2022)

Is there a role for immune checkpoint blockade in metastatic uveal melanoma?
por: Schilling, Bastian, et al.
Publicado: (2015)

Neoadjuvant Immune Checkpoint Blockade in High-Risk Resectable Melanoma
por: Amaria, Rodabe N., et al.
Publicado: (2018)

The molecular and functional landscape of resistance to immune checkpoint blockade in melanoma
por: Lim, Su Yin, et al.
Publicado: (2023)

RIP2 Is a Critical Regulator for NLRs Signaling and MHC Antigen Presentation but Not for MAPK and PI3K/Akt Pathways
por: Wu, Xiao Man, et al.
Publicado: (2018)

MHC Class II Auto-Antigen Presentation is Unconventional
por: Sadegh-Nasseri, Scheherazade, et al.
Publicado: (2015)

MHC structure and function – antigen presentation. Part 1
por: Goldberg, Anna Carla, et al.
Publicado: (2015)

MHC structure and function − antigen presentation. Part 2
por: Goldberg, Anna Carla, et al.
Publicado: (2015)

Involvement of autophagy in MHC class I antigen presentation
por: Øynebråten, Inger
Publicado: (2020)

Proteolysis and antigen presentation by MHC class II molecules
por: Bryant, Paula Wolf, et al.
Publicado: (2002)

Identification of antigens presented by MHC for vaccines against tuberculosis
por: Bettencourt, Paulo, et al.
Publicado: (2020)

Inflammation-induced hypoparathyroidism triggered by combination immune checkpoint blockade for melanoma
por: Trinh, Beckey, et al.
Publicado: (2019)

Safety and immunogenicity of a potential checkpoint blockade vaccine for canine melanoma
por: Kurupati, Raj K., et al.
Publicado: (2018)

Characterization of genetics in patients with mucosal melanoma treated with immune checkpoint blockade
por: Buchbinder, Elizabeth I., et al.
Publicado: (2021)

Skin dendritic cells in melanoma are key for successful checkpoint blockade therapy
por: Prokopi, Anastasia, et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_t7k5ai4amo23p4b78lhoo2vqs8